GSK1018921 is a new drug under development for the treatment of schizophrenia. GSK1018921
differs from other available drugs in its mode of action and it is assumed that it may have
an effect in the treatment of so-called positive symptoms such as hallucinations and negative
symptoms such as lack of drive. No clinical studies have been conducted with GSK1018921 in
humans until now. This is the first study where this compound is administered to humans; the
study has 2 parts: Part A is a dose escalation study, Part B is a pharmacodynamic portion in
a separate group of healthy smoker volunteers.